{"entity":{"id":"tyra-300","kind":"drug","name":"TYRA-300","aka":[],"tldr":"TYRA-300 is an experimental small-molecule drug from Tyra Biosciences in phase 2 trials for bladder & urothelial cancer, aimed at FGFR2.","summary":"TYRA-300 is a small-molecule drug developed by Tyra Biosciences. Its target is FGFR2 (the sponsor names FGFR3). The sponsor states: TYRA-300 is an oral, FGFR3-selective tyrosine kinase inhibitor that targets tumours containing activating FGFR3 gene alterations. ClinicalTrials.gov describes the intervention as: TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumours that contain activating gene alterations of FGFR3. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in bladder & urothelial cancer. The largest, NCT05544552, plans to enrol 310 participants with primary completion expected 2026-11. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of TYRA-300","url":"https://clinicaltrials.gov/search?intr=TYRA-300"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":["fgfr2"],"drugs":[],"companies":["tyra-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06995677","nct05544552"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule","mechanism":"TYRA-300 is an oral, FGFR3-selective tyrosine kinase inhibitor that targets tumours containing activating FGFR3 gene alterations.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tyra-300/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"target":[{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/"}],"company":[{"id":"tyra-biosciences","kind":"company","name":"Tyra Biosciences","route":"/companies/tyra-biosciences/"}],"trial":[{"id":"nct06995677","kind":"trial","name":"Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer","route":"/trials/nct06995677/"},{"id":"nct05544552","kind":"trial","name":"Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations","route":"/trials/nct05544552/"}]}}